DONNA SCHORK: Open Payments
NPI 1801649421 · SPRINGDALE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,570 in 105 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $1,281 · 2025 $2,570
Food & beverage: $2,570
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 15 | $501 |
| ABBVIE INC. | 21 | $467 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $426 |
| Axsome Therapeutics, Inc. | 5 | $280 |
| Neurocrine BioSciences, Inc. | 9 | $194 |
| Janssen Pharmaceuticals, Inc | 4 | $172 |
| Supernus Pharmaceuticals, Inc. | 4 | $156 |
| Teva Pharmaceuticals USA, Inc. | 6 | $124 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| Lundbeck LLC | 3 | $56 |
Products named: VRAYLAR, FANAPT, CAPLYTA, Auvelity, INGREZZA, SPRAVATO, Qelbree, AUSTEDO XR.
Industry payments across AR — which companies pay providers there.
